OQROGet OQRO Pro
Insider trade

Halozyme (HALO)Director sold ~$141K

Bernadette Connaughton, Director at Halozyme, sold ~$141K of Halozyme shares.

~$141K
Approx. value · 2,000 sh @ $70.25
40K
Holds after · shares reported
Traded
Jan 5, 2026
Filed
Jan 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 1, 2025InsiderOfficer sold ~$278K of HALO shares in the open market
  2. Nov 6, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  3. Nov 10, 2025Insider · 2 peopleInsiders: 3 sales (~$1.5M)
  4. Nov 11, 2025Insider · 1 personInsiders: 3 sales (~$1.4M)
  5. Nov 12, 2025Insider · 1 personInsiders: 3 sales (~$1.4M)
  6. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“(e) As previously disclosed, Halozyme Therapeutics, Inc. (“the Company”) announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026 or such earlier date determined by the Company (the “Separation Date”) and then depart to pursue a…”
  7. Dec 1, 2025Insider · 2 peopleInsiders: 5 sales (~$1.2M)
  8. Dec 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 4, 2025, James Lang was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Lang was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2027.”
  9. Dec 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 4, 2025, the Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”) approved a performance-based restricted stock unit grant (the “PSU Grant”) for Dr. Helen Torley, Chief Executive Officer of the Company.”
  10. Jan 5, 2026 · this disclosureInsiderDirector sold ~$141K of HALO shares in the open market

What came next

  1. Jan 28, 2026Company filing · Form 8-K · ResultsReported its results
  2. Feb 3, 2026Insider · 1 personInsiders: 3 sales (~$1.5M)
  3. Feb 4, 2026Insider · 1 personInsiders: 2 sales (~$1.5M)
  4. Feb 5, 2026Insider · 1 personInsiders: 2 sales (~$786K)
  5. Feb 17, 2026Company filing · Form 8-K · ResultsReported its results
  6. Mar 2, 2026Insider · 1 personInsiders: 3 sales (~$1.4M)
  7. Mar 3, 2026Insider · 1 personInsiders: 2 sales (~$1.4M)
  8. Mar 4, 2026Insider · 1 personInsiders: 2 sales (~$702K)
  9. Mar 9, 2026Insider · 1 personInsiders: 2 sales (~$1.4M)
  10. Mar 9, 2026CongressDisclosed purchase of HALO — reported range $1,001 - $15,000
  11. Mar 10, 2026InsiderOfficer sold ~$599K of HALO shares in the open market
  12. Mar 12, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 12, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”), effective March 23, 2026.”
  13. Apr 1, 2026Insider · 1 personInsiders: 2 sales (~$1.3M)
  14. Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.3M)
  15. Apr 6, 2026Insider · 1 personInsiders: 2 sales (~$635K)
  16. Apr 22, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  17. Apr 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.”
  18. May 1, 2026InsiderDirector sold ~$103K of HALO shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Halozyme

For Halozyme, OQRO holds 39 insider filings (SEC Form 4 or Form 144) and 15 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HALO page.

Other recent filings by Bernadette Connaughton, Director

The full history of Bernadette Connaughton, Director is on the profile page.

How this filing works

Other disclosures at Halozyme

Everything OQRO holds on this company is on its HALO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data